Overview

CytoSorbents Investor Relations

Honored with Frost & Sullivan’s Global Product Leadership Award for leading the critical-care immunotherapy segment in blood purification, CytoSorbents Corporation is currently distributing its EU-approved CytoSorb cytokine adsorber in 75 countries around the world

Featured News

CytoSorbents

Press Release

14 May '25

CytoSorbents Reports First Quarter 2025 Financial Results and Provides Business Update

PRINCETON, N.J., May 14, 2025 /PRNewswire/ — CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today reported financial results for the first quarter ended March 31, 2025, and recent business highlights. First Quarter 2025 Financial Results Product revenue was $8.7 million, ... CytoSorbents Reports First Quarter 2025 Financial Results and Provides Business Update

01 May '25

CytoSorbents Provides Regulatory Update for DrugSorb-ATR

PRINCETON, N.J., May 1, 2025 /PRNewswire/ — CytoSorbents Corporation (NASDAQ: CTSO), a leader in blood purification therapies for life-threatening conditions in the intensive care unit and cardiac surgery, today provided a regulatory update for DrugSorb™-ATR, its FDA-designated Breakthrough Device. DrugSorb-ATR is designed to reduce the severity of bleeding in patients undergoing coronary artery bypass grafting (CABG) surgery ... CytoSorbents Provides Regulatory Update for DrugSorb-ATR

29 Apr '25

CytoSorbents to Report First Quarter 2025 Financial Results and Recent Business Highlights

PRINCETON, N.J., April 29, 2025 /PRNewswire/ — CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, will report first quarter 2025 financial results and recent business highlights after the market close on Wednesday, May 14, 2025. CytoSorbents’ management will host a ... CytoSorbents to Report First Quarter 2025 Financial Results and Recent Business Highlights

21 Apr '25

CytoSorbents Receives Approximately $1.7 Million from the New Jersey Business Tax Certificate Transfer Program

PRINCETON, N.J., April 21, 2025 /PRNewswire/ — CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today announced that it has received $1.7 million in cash proceeds from the sale of its 2023 and amended 2022 Net Operating Loss (NOL) and ... CytoSorbents Receives Approximately $1.7 Million from the New Jersey Business Tax Certificate Transfer Program

View All News